Page 50 - Noble-Virtual-Healthcare-2024

Health Care
Date April 15, 2024 Health Care
52wk High $1.90
52wk Low $0.47 Unicycive Therapeutics, Inc. UNCY $1.12
4300 El Camino Real
Los Altos, CA 94022

(USD - in millions) unicycive.com
Market Cap 42.4
Enterprise 33.5
Basic Shares Out. 34.76 COMPANY OVERVIEW
Float 13.74
Institutional Holdings 7.11% Detailed Analysis:Channelchek.com
Short Interest 0.26
Avg. 90-Day Volume 0.35 Unicycive Therapeutics is a biotechnology company developing novel
treatments for kidney diseases. Unicycive’s lead drug candidate,
oxylanthanum carbonate (OLC), is a novel investigational phosphate
binding agent being developed for the treatment of hyperphosphatemia
EPS Data in chronic kidney disease patients on dialysis. UNI-494 is a patent-
protected new chemical entity in clinical development for the treatment
2021 2022 2023 of conditions related to acute kidney injury.
CQ1 N/A (0.24) (0.97)
CQ2 (0.13) (0.24) (0.29)

CQ3 (0.37) (0.37) (0.13)
CQ4 (0.17) (0.35) (0.16)
CY (0.86) (1.20) (1.28) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) -0.11
ROE (ttm) NM
Debt-to-Total Cap. (mrq) NM
Fiscal Year End 31-Dec
4300 El Camin Los Altos CA 94022

Key Executives
CEO: Gupta, Shalabh
CFO: Townsend, John
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert Leboyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures